Trial Profile
A phase I study of AdV-tk + prodrug therapy in combination with radiation therapy for pediatric brain tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Aciclovir; Temozolomide; Valaciclovir
- Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma
- Focus Adverse reactions
- Sponsors Advantagene; Candel Therapeutics
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 25 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.